Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 161Lymphoid 121Other hematologic neoplasm 73Myeloid 16Genitourinary 12Classical hematology 7Dermatologic 5Sarcoma 3Gastrointestinal 3Head & Neck 2Endocrine 2CNS 2Tumor-Agnostic 1Thoracic 1NET 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 151Carboplatin 123Bevacizumab 86Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 38Topotecan 37olaparib 30Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20Platinum 19niraparib 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17Nivolumab 17Magnetic Resonance Spectroscopy 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lenalidomide × Gynecologic × Clear all
NCT00903630 2017-12-28

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
15 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡